Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vasomotor Symptoms and Cardiovascular Control

NCT02202707
View directory record Official record
Conditions
Vasomotor Symptoms, Cardiovascular Health
Interventions
Gabapentin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
45 Years to 58 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Results available

Perioperative Pregabalin in Ureteroscopy: a Pilot

NCT03927781
View directory record Official record
Conditions
Nephrolithiasis, Urolithiasis, Perioperative/Postoperative Complications, Pain, Postoperative, Pain, Acute, Anesthesia, Urologic Diseases, Anesthesia Morbidity
Interventions
Pregabalin 300mg
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 25, 2026, 8:47 AM EDT
Terminated Phase 1 Interventional

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

NCT04245722
View directory record Official record
Conditions
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
Interventions
FT596, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Chicago, Illinois • Minneapolis, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 1 Interventional

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

NCT01900509
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Acute Leukemia
Interventions
Bendamustine, Clofarabine, Etoposide, Etoposide phosphate, Dexamethasone
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Baclofen for Children With Rumination Syndrome

NCT05975684
View directory record Official record
Conditions
Rumination Syndrome
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 25, 2026, 8:47 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752
View directory record Official record
Conditions
Lymphoma, Mantle Cell Lymphoma
Interventions
rituximab, Bendamustine, bortezomib, lenalidomide
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2031
U.S. locations
416
States / cities
Anchorage, Alaska • Antioch, California • Fremont, California + 283 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 8:47 AM EDT
Recruiting Phase 2 Interventional

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

NCT04587687
View directory record Official record
Conditions
Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Interventions
Bendamustine Hydrochloride, Brentuximab Vedotin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 2 Interventional

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)

NCT00076349
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
bendamustine and rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
25
States / cities
Anchorage, Alaska • Concord, California • La Verne, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Not applicable Interventional Results available

Obesity and Nonalcoholic Fatty Liver Disease

NCT00262964
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Niacin, fenofibrate, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer

NCT03269344
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Gabapentin, Placebo Oral Capsule
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

NCT02215252
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Results available

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
pregabalin (Lyrica), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
150
States / cities
Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI

NCT04256603
View directory record Official record
Conditions
Spinal Cord Injuries, Neuropathic Pain
Interventions
Gabapentin, No gabapentin
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Not applicable Interventional Results available

Pregabalin in CIPN

NCT02394951
View directory record Official record
Conditions
Neuropathy, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 1 Interventional

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

NCT00002677
View directory record Official record
Conditions
Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
chemotherapy, tributyrin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients

NCT00952081
View directory record Official record
Conditions
Hypertension, Brain Tumor, Epilepsy
Interventions
Clevidipine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

NCT01096992
View directory record Official record
Conditions
Leukemia
Interventions
Bendamustine, Fludarabine, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 25, 2026, 8:47 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures

NCT00524030
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
pregabalin 600 mg/day, pregabalin 150 mg/day
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
63
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions

NCT00778401
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin tablets 800 mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 25, 2026, 8:47 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation

NCT05514119
View directory record Official record
Conditions
Liver Transplant
Interventions
Fenofibrate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 25, 2026, 8:47 AM EDT
Withdrawn Phase 2 Interventional

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission

NCT04259060
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hydroxocobalamin with Butyrate, Placebo with Butyrate
Drug
Lead sponsor
Joshua Korzenik
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Phase 2 Interventional Results available

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
View directory record Official record
Conditions
Hyperlipidemia
Interventions
AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 25, 2026, 8:47 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures

NCT02856750
View directory record Official record
Conditions
Acute Pain
Interventions
Gabapentin
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 25, 2026, 8:47 AM EDT